Arid1b-Related Disorder
Summary
Clinical characteristics.
ARID1B-related disorder (ARID1B-RD) constitutes a clinical continuum, from classic Coffin-Siris syndrome to intellectual disability with or without nonspecific dysmorphic features. Coffin-Siris syndrome is classically characterized by aplasia or hypoplasia of the distal phalanx or nail of the fifth and additional digits, developmental or cognitive delay of varying degree, distinctive facial features, hypotonia, hypertrichosis, and sparse scalp hair. Frequencies of other features, such as developmental delay (with speech often more affected than motor development), is consistent across the clinical spectrum, and may include malformations of the cardiac, gastrointestinal, genitourinary, and/or central nervous systems. Other findings seen in individuals with ARID1B-RD include feeding difficulties, slow growth, ophthalmologic abnormalities, hearing impairment, seizures, attention-deficit/hyperactivity disorder, and autistic features.
Diagnosis/testing.
The diagnosis of ARID1B-RD is established by identification of a heterozygous pathogenic variant in ARID1B by molecular genetic testing.
Management.
Treatment of manifestations: Standard treatment for strabismus, refractive error, hearing loss, congenital heart defects, obstructive sleep apnea, constipation, gastroesophageal reflux, cryptorchidism, scoliosis, and seizure disorders. For significant feeding issues, a nasogastric and/or gastrostomy tube may be required. Developmental therapies, including speech/language and feeding therapy, is recommended for those with developmental delay.
Surveillance: At least annual assessment of developmental progress and educational needs; annual ophthalmology evaluation and assessment for scoliosis (until growth is complete). Audiology evaluation, behavior assessment, and hormonal evaluation/bone age as needed based on symptoms. Those with seizures should be monitored as clinically indicated.
Genetic counseling.
ARID1B-related disorder is inherited in an autosomal dominant fashion. With the exception of two families in which a parent and child had features consistent with ARID1B-related disorder, all individuals diagnosed to date have the disorder as the result of a de novo pathogenic variant. Once the ARID1B pathogenic variant has been identified in an affected family member, prenatal and preimplantation genetic testing are possible.
Diagnosis
Heterozygous pathogenic variants in ARID1B lead to a phenotypic spectrum, from Coffin-Siris syndrome (CSS) (with dysmorphic features and/or organ system involvement) to intellectual disability with or without nonspecific dysmorphic features. See Coffin-Siris Syndrome for more information.
Note: The information presented in the Coffin-Siris syndrome GeneReviews chapter includes information on individuals with CSS from a variety of genetic causes including ARID1B but is not specific to individuals with a pathogenic variant in ARID1B.
Suggestive Findings
ARID1B Coffin-Siris syndrome (ARID1B-CSS) should be suspected in individuals with the following findings [Fleck et al 2001, Schrier et al 2012, Kosho et al 2014, Santen et al 2014]:
- Fifth-digit nail and/or distal phalanx hypoplasia (although other digits may be affected) OR aplasia of the hands or feet
- Developmental or cognitive delay of variable degree
- Typical facial features including a wide mouth with thick, everted vermilion of the upper and lower lips, broad nasal bridge with broad nasal tip, thick eyebrows, and long eyelashes
- Central hypotonia
- Hypertrichosis in atypical areas (e.g., the back) or excessive hair growth on the arms or face
- Sparse scalp hair, especially in infancy, particularly in the temporal regions
Though admittedly a large group, ARID1B intellectual disability with or without nonspecific dysmorphic features (ARID1B-ID) should be considered in individuals presenting with the following clinical findings:
- Mild-to-profound developmental delay (DD) and/or intellectual disability (ID)AND
- Any of the following features presenting in infancy or childhood:
- Generalized hypotonia of infancy
- Infant feeding difficulties
- Spasticity
- Epilepsy (predominately tonic-clonic)
- Behavior problems, such as attention-deficit/hyperactivity disorder (ADHD) and autistic features
- Cryptorchidism
- Laryngomalacia
- Myopia
- Delayed speech development
- Suggestive dysmorphic features (see Clinical Description)
Establishing the Diagnosis
The diagnosis of an ARID1B-related disorder is established in a proband with suggestive clinical features by identification of a heterozygous pathogenic variant in ARID1B by molecular genetic testing (see Table 1).
Molecular genetic testing approaches can include a combination of gene-targeted testing (single-gene testing or multigene panel) and comprehensive genomic testing (chromosomal microarray analysis and exome sequencing) depending on the phenotype.
Classic ARID1B Coffin-Siris Syndrome
When the phenotypic findings suggest the diagnosis of ARID1B-CSS, molecular genetic testing approaches can include single-gene testing or use of a multigene panel:
- Single-gene testing. Sequence analysis of ARID1B detects small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, exon or whole-gene deletions/duplications are not detected. Perform sequence analysis first. If no pathogenic variant is found, perform gene-targeted deletion/duplication analysis to detect intragenic or whole-gene deletions or duplications.
- A Coffin-Siris syndrome multigene panel that includes ARID1A, ARID1B, ARID2, DPF2, PHF6, SMARCA2, SMARCA4, SMARCB1, SMARCE1, SOX11, and other genes of interest (see Differential Diagnosis) is most likely to identify the genetic cause of the condition at the most reasonable cost while limiting identification of variants of uncertain significance and pathogenic variants in genes that do not explain the underlying phenotype. Note: (1) The genes included in the panel and the diagnostic sensitivity of the testing used for each gene vary by laboratory and are likely to change over time. (2) Some multigene panels may include genes not associated with the condition discussed in this GeneReview. (3) In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused exome analysis that includes genes specified by the clinician. (4) Methods used in a panel may include sequence analysis, deletion/duplication analysis, and/or other non-sequencing-based tests.For an introduction to multigene panels click here. More detailed information for clinicians ordering genetic tests can be found here.
ARID1B Intellectual Disability with or without Nonspecific Dysmorphic Features
Molecular genetic testing in a child with developmental delay or an older individual with intellectual disability typically begins with chromosomal microarray analysis (CMA). If CMA is not diagnostic, the next step is typically either a multigene panel or exome sequencing:
- Chromosomal microarray analysis (CMA) uses oligonucleotide or SNP (single-nucleotide polymorphism) arrays to detect genome-wide large deletions/duplications (including ARID1B) that may not be detected by sequence analysis.
- An intellectual disability multigene panel that includes ARID1B and other genes of interest (see Differential Diagnosis) is most likely to identify the genetic cause of the condition in a person with a non-diagnostic CMA at the most reasonable cost while limiting identification of variants of uncertain significance and pathogenic variants in genes that do not explain the underlying phenotype. Note: (1) The genes included in the panel and the diagnostic sensitivity of the testing used for each gene vary by laboratory and are likely to change over time. (2) Some multigene panels may include genes not associated with the condition discussed in this GeneReview. (3) In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused exome analysis that includes genes specified by the clinician. (4) Methods used in a panel may include sequence analysis, deletion/duplication analysis, and/or other non-sequencing-based tests. For this disorder an intellectual disability multigene panel that also includes deletion/duplication analysis is recommended (see Table 1).For an introduction to multigene panels click here. More detailed information for clinicians ordering genetic tests can be found here.
- Exome sequencing, which does not require the clinician to determine which gene is likely involved, yields results similar to an ID multigene panel but has two advantages: (1) a multigene panel may not include all rare genes recently identified as causing ID; and (2) exome sequencing may be able to detect pathogenic variants in genes which – for technical reasons – do not sequence well.For an introduction to comprehensive genomic testing click here. More detailed information for clinicians ordering genomic testing can be found here.
Table 1.
Gene 1 | Phenotype | Method | Proportion of Probands with a Pathogenic Variant 2 Detectable by Method |
---|---|---|---|
ARID1B | Coffin-Siris syndrome | Sequence analysis 3 | 71/80 4 |
Gene-targeted deletion/duplication analysis 5 | 9/80 6 | ||
ARID1B intellectual disability | Sequence analysis 3 | 54/63 7, 8 | |
CMA 9 | 9/63 7 |
- 1.
See Table A. Genes and Databases for chromosome locus and protein.
- 2.
See Molecular Genetics for information on allelic variants detected in this gene.
- 3.
Sequence analysis detects variants that are benign, likely benign, of uncertain significance, likely pathogenic, or pathogenic. Variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, exon or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click here.
- 4.
van der Sluijs et al [2019]
- 5.
Gene-targeted deletion/duplication analysis detects intragenic deletions or duplications. Methods used may include quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a gene-targeted microarray designed to detect single-exon deletions or duplications.
- 6.
Microdeletions of chromosome 6q25.3 that include ARID1B have been reported in: (a) children with CSS ascertained prior to the understanding of the molecular basis of CSS [Tsurusaki et al 2012]; (b) children ascertained with a microdeletion containing ARID1B and secondarily noted to have features similar to CSS [Santen et al 2012]; and (c) individuals with mildly or variably syndromic intellectual disability [Nagamani et al 2009, Halgren et al 2012, Hoyer et al 2012, Michelson et al 2012] for whom available clinical information is insufficient to determine the similarity to CSS. Of note, these individuals may have complex clinical findings due to the involvement of additional genes surrounding the ARID1B locus.
- 7.
Santen et al [2013]
- 8.
Although the Santen et al [2013] study included sequence analysis results of individuals with clinical features of Coffin-Siris syndrome, it is the only study where all affected individuals underwent both MLPA and sequencing analysis, and therefore likely reflects the mutational spectrum best.
- 9.
Chromosomal microarray analysis (CMA) uses oligonucleotide or SNP arrays to detect genome-wide large deletions/duplications (including ARID1B) that cannot be detected by sequence analysis. The ability to determine the size of the deletion/duplication depends on the type of microarray used and the density of probes in the 6q25.3 region. CMA designs in current clinical use target the 6q25.3 region.
Clinical Characteristics
Clinical Description
Most individuals with a heterozygous pathogenic variant in ARID1B have some features consistent with Coffin-Siris syndrome.
Note: (1) The Coffin-Siris syndrome GeneReviews chapter includes information on individuals with CSS from a variety of genetic causes including ARID1B but is not specific to individuals with a pathogenic variant in ARID1B. (2) Approximately 1/2 to 2/3 of individuals with molecularly confirmed CSS have a pathogenic variant in ARID1B [van der Sluijs et al 2019]. More data are needed to determine which CSS features are found more or less frequently in individuals with a pathogenic variant in ARID1B.
To date, approximately 100 individuals who do not have the classic Coffin-Siris syndrome phenotype have been identified with a heterozygous pathogenic variant in ARID1B [Santen et al 2013, Santen et al 2014, Ben-Salem et al 2016, Mannino et al 2018, van der Sluijs et al 2019].
A comparison between individuals with a heterozygous pathogenic variant in ARID1B with an a priori clinical diagnosis of CSS and a group without the a priori clinical diagnosis suggests that apart from CSS-specific features (hypo/aplasia of the fifth digits or nails of the hands/feet, sparse scalp hair, coarse facial features, hypertrichosis) there are no major differences between the two groups [van der Sluijs et al 2019]. Therefore, the Authors treat them as a single entity, ARID1B-related disorder (ARID1B-RD).
Developmental delay (DD) and intellectual disability (ID). Intellectual disability ranges from profound to very mild, and intelligence quotients (IQs) in the normal range have been identified in some individuals with ARID1B-RD. Most affected individuals have developmental delay, with speech often more affected than motor development. An estimated 25% of affected individuals do not develop verbal language skills [van der Sluijs et al 2019].
Neurologic/epilepsy
- Hypotonia is a frequent finding (40%-80% of affected individuals).
- Epilepsy. Approximately one third of individuals with ARID1B-RD have experienced seizures, predominately of the tonic-clonic type. Additional individuals may have abnormal EEGs without apparent clinical seizure activity. Those with overt seizures appear to respond well to standard antiepileptic drugs. The age of onset of seizures ranges from birth to mid-teenage years [van der Sluijs et al 2019].
Behavior problems. Individuals with ARID1B-RD appear to be at increased risk for a diagnosis of ADHD or autism, but the overall prevalence is not known, as many individuals now receiving the diagnosis at a younger age may not yet be old enough to evaluate for certain neurodevelopmental abnormalities. There does not appear to be an increased prevalence of self-harm, aggression, or sleep disturbances. Some behavior abnormalities may be exacerbated by an individual's degree of speech delay and difficulty with communication.
Growth. There are limited data regarding prenatal growth in individuals with ARID1B-RD. Postnatal growth data show the following:
- Weight may be normal or below average but appears to be in proportion to other growth parameters.
- The majority of affected individuals appear to have a length/height 0 to 2 SD below the mean; data are not sufficient to predict final adult height.Bone age appears to be delayed in approximately 50% of individuals who have been evaluated.
- Head circumference is normal in a majority of individuals with ARID1B-RD.
Gastrointestinal problems. Feeding difficulties are common and appear to approximate those seen in individuals with a diagnosis of CSS from a variety of genetic causes.
- Individuals with feeding difficulties commencing around the time of birth appear to have more severe issues and tend to require a feeding tube of some type (nasogastric or gastrostomy tube).
- In older children, milder feeding difficulties may occur, including oral aversion, particularly in those who required tube feeding as an infant or younger child.
- Constipation and gastroesophageal reflux disease are also common and may approximate that seen in individuals with CSS or other genetic syndromes with varying degrees of neurologic impairment [Mannino et al 2018].
Sensory impairment
- Approximately 25%-30% of affected individuals have some vision abnormality, although this frequency may not be significantly different from that of individuals with CSS from a variety of genetic causes [Mannino et al 2018]. The most frequently reported abnormalities include myopia, strabismus, and astigmatism.
- Similarly, 25%-40% of affected individuals have some degree of hearing loss, the most common being congenital sensorineural hearing loss, although conductive hearing loss has also been reported [Mannino et al 2018, van der Sluijs et al 2019]. The range of severity of sensorineural hearing loss is not precisely known.
Neuroimaging. Of those individuals who have undergone brain imaging, approximately 30%-40% demonstrate brain anomalies. The most common abnormality is hypo- or aplasia of the corpus callosum [van der Sluijs et al 2019]. Delayed myelination or other white matter changes, colpocephaly, mega cisterna magna, and enlarged Virchow-Robin spaces are also seen. Additional brain abnormalities may be detected as more individuals undergo imaging.
Other associated features
- Respiratory abnormalities. Laryngomalacia has been documented, although it does not appear to occur more frequently than in individuals with CSS due to a variety of genetic causes [Mannino et al 2018, van der Sluijs et al 2019]. Asthma and obstructive sleep apnea have also been reported but may approximate the frequency of the general population.
- Genitourinary (GU) abnormalities. The most commonly reported GU abnormality appears to be cryptorchidism in males; structural renal abnormalities have been seen but the frequency of specific malformations is not known.
- Musculoskeletal. Scoliosis is seen with greater frequency than in the general population and may be acquired as affected individuals age. Shortened fifth digits or hypoplastic nails in the hands or feet may also be seen, as these are classically associated with CSS.
- Dysmorphic features. Affected individuals may have some features also seen in individuals with CSS from a variety of genetic causes, including sparse scalp hair, long eyelashes, hypertrichosis, and coarse facial features; more specifically, individuals may have thick alae nasi, a long philtrum, and a thick vermilion of the lower lip.
Prognosis. It is unknown if life span in individuals with ARID1B-RD is abnormal. One reported individual is alive at age 51 years [Santen, personal observation], and a woman age 60 years has also been reported [Määttänen et al 2018], demonstrating that survival into adulthood is possible. Since many adults with disabilities have not undergone advanced genetic testing, it is likely that adults with this condition are underrecognized and underreported.
Genotype-Phenotype Correlations
To date, only loss-of-function variants (e.g., nonsense, splice site, frameshift, whole-gene deletions) cause ARID1B-RD. Missense variants do not appear to be pathogenic in general; however, a single missense variant in a proband (who had agenesis of the corpus callosum [ACC]) and the proband's mother (who did not have ACC but had mild ID) was described as de novo in the mother [Mignot et al 2016].
There do not appear to be specific genotype-phenotype correlations among individuals with ARID1B-related disorder to distinguish individuals with ARID1B intellectual disability with or without nonspecific dysmorphic features (ARID1B-ID) from those with ARID1B Coffin-Siris syndrome (ARID1B-CSS).
Prevalence
This condition is estimated to occur in approximately 1:10,000 to 1:100,000 individuals [Hoyer et al 2012].
Differential Diagnosis
ARID1B Coffin Siris Syndrome (ARID1B-CSS)
Table 2.
Differential Diagnosis Disorder | Gene(s) / Genetic Mechanism | MOI | Clinical Features of Differential Diagnosis Disorder | |
---|---|---|---|---|
Overlapping w/ARID1B-CSS | Distinguishing from ARID1B-CSS | |||
Coffin-Siris syndrome caused by genes other than ARID1B | ARID1A DPF2 SMARCC2 SMARCA4 SMARCB1 SMARCE1 SOX11 | AD | Frequently clinically indistinguishable from ARID1B-CSS | Microcephaly seen more frequently in individuals w/a heterozygous pathogenic variant in SMARCB1 or SMARCE1 |
Nicolaides-Baraitser syndrome | SMARCA2 | AD |
|
|
Borjeson-Forssman-Lehmann syndrome (OMIM 301900) | PHF6 | XL | Affected females demonstrate some phenotypic overlap w/CSS, incl hypoplastic nails & fingers, sparse hair, & intellectual disability. 1, 2 |
|
ARID2-ID (OMIM 617808) | ARID2 | AD |
| Birth defects not common |
DOORS (deafness, onychodystrophy, osteodystrophy, mental retardation, & seizures) syndrome (see TBC1D24-Related Disorders) | TBC1D24 | AR |
|
|
Mabry syndrome (OMIM 239300) | PIGV | AR |
| ↑ serum concentrations of alkaline phosphatase |
Cornelia de Lange syndrome | HDAC8 NIPBL RAD21 SMC1A SMC3 | AD, XL |
| Distinctive craniofacial features (arched eyebrows, synophrys, upturned nose, small teeth, & microcephaly) |
4q21 deletion syndrome (OMIM 613509) | Contiguous-gene deletion | AD 1 |
|
|
AD = autosomal dominant; AR = autosomal recessive; CSS = Coffin-Siris syndrome; ID = intellectual disability; MOI = mode of inheritance; XL = X-linked
- 1.
To date, all reported probands have had the disorder as the result of a de novo deletion.
- 2.
Zweier et al [2014]
- 3.
While some of these features demonstrate overlap with CSS, an assessment of a larger cohort of individuals with ARID2 pathogenic variants will be needed to determine whether it is clinically similar to or distinct from CSS.
The following genetic and teratogenic disorders may also be considered in the differential diagnosis of ARID1B-CSS:
- Mosaic trisomy 9. An individual with mosaic trisomy 9 had features similar to those of CSS, including facial features (wide, bulbous nose), hirsutism, and hypoplasia of the fifth digits [Kushnick & Adessa 1976].
- Brachymorphism-onychodysplasia-dysphalangism (BOD) syndrome (OMIM 113477) is characterized by short stature, tiny dysplastic nails, short fifth fingers, a wide mouth with broad nose, and mild intellectual deficits [Verloes et al 1993, Elliott & Teebi 2000]. This latter characteristic is most likely to distinguish individuals with BOD syndrome from those with CSS, as the cognitive disability in CSS is nearly always moderate to severe. Inheritance appears to be autosomal dominant.
- Fetal alcohol syndrome (FAS). Small nails, prenatal and postnatal growth retardation, dysmorphic facial features, and cognitive disabilities may be seen in FAS.
- Fetal hydantoin/phenytoin embryopathy. Small nails with hypoplasia of distal phalanges, dysmorphic facial features, digitalized thumbs, low hairline, short or webbed neck, growth retardation, and cognitive disabilities have been described in this syndrome, caused by prenatal exposure to phenytoin.
ARID1B Intellectual Disability with or without Nonspecific Dysmorphic Features
Because the phenotypic features associated with ARID1B-ID are not sufficiently distinctive to diagnose this condition, all disorders with intellectual disability (ID) without other distinctive findings should be considered in the differential diagnosis. To date more than 180 such disorders with ID have been identified. See OMIM Phenotypic Series: Autosomal dominant ID; Autosomal recessive ID; Nonsyndromic X-linked ID; and Syndromic X-linked ID.
Management
Evaluations Following Initial Diagnosis of ARID1B-Related Disorders
To establish the extent of disease and needs in an individual diagnosed with ARID1B-RD, the evaluations summarized in Table 2 (if not performed as part of the evaluation that led to diagnosis) are recommended. Note that some evaluations depend on whether the clinician thinks that the affected individual has ARID1B-CCS or ARID1B-ID.
Table 3.
System/Concern | Evaluation | Comment |
---|---|---|
Eyes | Ophthalmologic eval | Assess for myopia, astigmatism, & strabismus. |
ENT | Audiologic eval | Assess for hearing loss (even if newborn hearing screen is normal). |
Cardiovascular | Cardiology eval |
|
Respiratory | Assess for signs & symptoms of obstructive sleep apnea. | If present, consider ENT or sleep clinic evaluation &/or polysomnography. |
Gastrointestinal/ Feeding | Assess growth parameters. | Consider bone age studies or other hormonal assessments if person has short stature ↓ predicted mid-parental height. |
Assess feeding & nutritional status. | Refer to gastroenterologist or feeding specialist, as needed, for persistent feeding issues. | |
Genitourinary | Assess males for cryptorchidism. | Urologic evaluation if cryptorchidism present |
Renal ultrasound | To evaluate for occult renal malformations | |
Musculoskeletal | Clinical assessment for scoliosis | Consider referral to orthopedist, if severe. |
Neurologic | Neurologic eval | Incl EEG & brain MRI, if indicated. |
Psychiatric/ Behavioral | Neuropsychiatric eval | Screen persons age >12 mos for behavior concerns incl ADHD &/or traits suggestive of ASD. |
Miscellaneous/ Other | Consultation w/clinical geneticist or genetic counselor | |
Developmental assessment | Incl evaluation of motor, speech/language, general cognitive, & vocational skills. |
ADHD = attention-deficit/hyperactivity disorder; ASD = autism spectrum disorder
- 1.
An echocardiogram is recommended for those individuals with ARID1B-CSS. Although cardiac anomalies have not been described in individuals with ARID1B-ID, they can be a component of mild ARID1B-CSS and therefore a cardiology evaluation should be considered [Mannino et al 2018].
- 2.
Echocardiogram may not be warranted in older children without obvious cardiovascular signs or symptoms based on exam.